Sugi Predict

Sugi Predict / Compounds / Thymine

Thymine

Thymine

SCHEMBL646138

Cc1c[nH]c(=O)[nH]c1=O.N

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ATAD2 Q6PL18 1/20 0.95
▸ DPYD Q12882 5/20 0.50
▸ MAPT P10636 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CYP19A1 P11511 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ THPO P40225 1/20 0.50
▸ MTOR P42345 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ HBB P68871 1/20 0.50
▸ PMP22 Q01453 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thymine SCHEMBL5235 0.97 — —
Thymine SCHEMBL29669526 0.97 — —
Thymine SCHEMBL750450 0.97 ATAD2 (1.00) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL15323914 0.97 ATAD2 (1.00) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL17201833 0.97 ATAD2 (1.00) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL2724033 0.95 ATAD2 (0.95) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL3500839 0.95 ATAD2 (0.95) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL31403209 0.95 ATAD2 (0.95) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL5176783 0.95 ATAD2 (0.95) ATAD2DPYDMAPTGAAALDH1A1
Thymine SCHEMBL4811815 0.95 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118541486-A Antisense oligonucleotides and uses thereof 财团法人生物技术开发中心 2024-08-23 — — CN disclosed
CN-111735678-B Separation, enrichment and determination method of gold, platinum and palladium in geochemical sample 中国地质科学院矿产综合利用研究所 2023-07-04 — — CN disclosed
CN-111735678-A Method for separating, enriching and measuring gold, platinum and palladium in geochemical sample 中国地质科学院矿产综合利用研究所 2020-10-02 — — CN disclosed
CN-110841607-A Ultra-low-cost priming gold special-effect resin and preparation and application thereof 中国科学院地质与地球物理研究所 2020-02-28 — — CN disclosed
CN-106525546-B Analysis method for modifying foam plastic enriched gold by using improved 5-aminomethyl uracil 中国科学院地质与地球物理研究所 2020-01-03 — — CN disclosed
CN-106525546-B Analysis method for modifying foam plastic enriched gold by using improved 5-aminomethyl uracil 中国科学院地质与地球物理研究所 2020-01-03 — — CN disclosed
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS CHOUDHARY MUHAMMAD IQBAL (PK) 2017-08-31 — — US disclosed
US-20120208190-A1 LUMINESCENT METAL ION COMPLEXES BIOSEARCH TECHNOLOGIES, INC. (US) 2012-08-16 — — US disclosed
US-8119781-B2 Luminescent metal ion complexes BIOSEARCH TECHNOLOGIES, INC. (US) 2012-02-21 — — US disclosed
US-20100130733-A1 LUMINESCENT METAL ION COMPLEXES BIOSEARCH TECHNOLOGIES, INC. (US) 2010-05-27 — — US disclosed
US-20010033862-A1 Methods of treating viral infections using antiviral liponucleotides HOSTETLER KARL Y (US) 2001-10-25 — — US disclosed
US-6252060-B1 COMPLEX CONTAINING DIDEOXYGUANOSINE NEXSTAR PHARMACEUTICALS, INC. 2001-06-26 — — US disclosed
EP-0350287-B1 Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use CHIMERIX INC (US) 2000-09-27 — — EP disclosed
US-5817638-A USING HYBRID NUCLEOSIDES NEXSTAR PHARMACEUTICALS, INC. (US) 1998-10-06 — — US disclosed
EP-0594677-A4 ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B VICAL INC (US) 1997-09-17 — — EP disclosed
EP-0594677-A1 ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B NeXstar Pharmaceuticals, Inc. (US) 1994-05-04 — — EP disclosed
US-5223263-A Viricide complex; aids therapy VICAL, INC. (US) 1993-06-29 — — US disclosed
WO-1993000910-A1 ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B VICAL, INC. (US) 1993-01-21 — — WO disclosed
WO-1990000555-A1 LIPID DERIVATIVES OF ANTIVIRAL NUCLEOSIDES, LIPOSOMAL INCORPORATION AND METHOD OF USE VICAL, INC. (US) 1990-01-25 — — WO disclosed
EP-0350287-A2 Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use NeXstar Pharmaceuticals, Inc. (US) 1990-01-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130733-A1 LUMINESCENT METAL ION COMPLEXES SLC30A6, SLC39A14, SLC39A3 ATAD2 580/4885DPYD 1808/4885MAPT 2868/4885
US-20120208190-A1 LUMINESCENT METAL ION COMPLEXES SLC30A6, SLC39A14, SLC39A3 ATAD2 580/4885DPYD 1808/4885MAPT 2868/4885
US-20010033862-A1 Methods of treating viral infections using antiviral liponucleotides PHOSPHO1, TK1, TYMP ATAD2 2259/4885DPYD 463/4885MAPT 3990/4885
US-20170246130-A1 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS TYMP, DPYD, FLT4 ATAD2 2477/4885DPYD 2/4885MAPT 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.